Key Highlights
- AngioDynamics shares are trading at $15.40 in pre-market activity, up 1.85% from Thursday's close of $15.12.
- A Jacobi Hospital team in the Bronx was named an ALPHA-PE Research Fund award recipient for a study of CT imaging in pulmonary embolism.
- The fund provides awards of $50,000 to $750,000 over one to three years for independent, physician-led research.
- Fiscal first-quarter results are due on October 8, with analysts expecting a loss of about $0.11 per share.
A Small Research Award Gives a Quiet Stock a Reason to Tick Up
AngioDynamics (NASDAQ:ANGO), a Latham, New York medical technology company focused on vascular disease and cancer treatment, is edging higher in pre-market trading. Shares are at $15.40, up 1.85% from Thursday's close of $15.12, slightly ahead of a healthcare sector fund up about 0.4%.
The news is modest. The company and The PERT Consortium named a Jacobi Hospital team an ALPHA-PE Research Fund award recipient, supporting an independent study on pulmonary embolism. It supports the company's evidence-building efforts, but it is not financial news.
What the Jacobi Study Will Test
The investigator-led study will examine whether features extracted from CT pulmonary angiography scans, a technique called radiomics, can predict the makeup of a patient's blood clot, the success of mechanical thrombectomy and long-term outcomes. Physicians currently have limited ability to judge from imaging how a clot will respond to the procedure, and complete clot removal is not always achieved.
The goal is evidence that helps identify which patients are most likely to benefit from intervention. Laura Piccinini, a senior vice president at the company, said the program reflects its commitment to physician-led research.
October 8 Earnings Are the Real Event
Investors are looking ahead to fiscal first-quarter results on October 8. Analysts expect a loss of about $0.11 per share on Revenue near $80.5 million. The report follows a strong prior quarter and fiscal 2027 guidance for a loss of $0.24 to $0.29 per share.
Analyst consensus is Hold with an average target of $19.50. The shares sit near their 50-day average and about 5% below their 52-week high of $16.29, with rising Treasury yields and oil keeping broader markets choppy.
What a Research Grant Does and Does Not Say About the Business
A research award shows commitment to the pulmonary embolism field, but it does not change near-term revenue, and the study's findings are far off. The 1.85% move is about what an ordinary quiet session produces.
For the stock, the October 8 report matters far more than this announcement. It will show whether the strong prior quarter was a one-off and whether guidance for a smaller loss still holds. Until then, the shares are likely to move with the sector.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...